Biopharmaceutical company Lipum is approaching clinical studies with the candidate SOL-116, which targets chronic inflammatory diseases such as rheumatoid arthritis. CEO Einar Pontén presented the company at the BioStock Investor Meeting in Stockholm and BioStock had the opportunity to interview Pontén about the upcoming clinical study and what distinguishes SOL-116 from today’s treatments.
Watch the interview with Lipum’s CEO Einar Pontén below.
Please note that the presentation was recorded before the news that Lipum’s board of directors has resolved on a directed issue of approximately 39 MSEK and prior to the approval of a phase I study with SOL-116.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.